- 2024.
- 2023.
- 2022.
- 2021.
- 2020.
- 2019.
- 2018.
- 2017.
- 2016.
- 2015.
- 2014.
- 2013.
- 2012.
- 2011.
- 2010.
- 2009.
- 2008.
- 2007.
- 2006.
- 2005.
- 2004.
- 2003.
- 2002.
- 2001.
- 2000.
- 1999.
- 1998.
- 2024.
- 2023.
- 2022.
- 2021.
- 2020.
- 2019.
- 2018.
- 2017.
- 2016.
- 2015.
- 2014.
- 2013.
- 2012.
- 2011.
- 2010.
- 2009.
- 2008.
- 2007.
- 2006.
- 2005.
- 2004.
- 2003.
- 2002.
- 2001.
- 2000.
- 1999.
- 1998.
2024.
-
- Mar.14.2024 Licensing
- Ono Enters into a Collaboration Agreement with Sibylla Biotech to Generate Novel Drug Candidates for Neurological Disorders
-
- Mar.12.2024 R & D
- U.S. Food and Drug Administration Approves Opdivo® (nivolumab), in Combination with Cisplatin and Gemcitabine, for First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma
-
- Mar.11.2024 Sustainability
- Ono Selected as "2024 Health & Productivity Stock"
-
- Mar.11.2024 Licensing
- ONO Enters into a University-Wide, Research Alliance Agreement with Harvard University
-
- Mar.06.2024 Licensing
- Ono Enters into a License Agreement with NEX-I to Develop and Commercialize NXI-101
-
- Mar.05.2024 Corporate
- ONO Receives Excellence Award at the Nikkei Integrated Report Award 2023
-
- Mar.04.2024 Management / Finance
- Ono Announces Status and Completion of Acquisition of Own Shares
-
- Mar.01.2024 Management / Finance
- Ono Announces Status of Acquisition of Own Shares
-
- Feb.21.2024 Licensing
- Ono Enters into a Drug Discovery Collaboration Agreement with EME Aiming at the Generation of Novel VHH Antibody Drugs
-
- Feb.19.2024 Licensing
- Ono Enters into a Research Collaboration Agreement with InveniAI to Identify Novel Therapeutic Targets
-
- Feb.14.2024 Licensing
- ONO Enters into an Option and Collaboration Agreement with Numab to Develop Multi-specific Antibody NM49
-
- Feb.13.2024 Licensing
- Ono Enters into a Drug Discovery Collaboration and Option Agreement with Shattuck Labs to Generate Bifunctional Fusion Proteins
-
- Feb.09.2024 R & D
- ONO Receives Supplemental Approval of Opdivo® in Japan for Expanded Use for Treatment of Unresectable Advanced or Recurrent Malignant Epithelial Tumors
-
- Feb.08.2024 R & D
- Bristol Myers Squibb Announces Acceptance of U.S. and EU Regulatory Filings for Neoadjuvant Opdivo (nivolumab) and Chemotherapy Followed by Surgery and Adjuvant Opdivo in Resectable Non-Small Cell Lung Cancer
-
- Feb.07.2024 Sustainability
- ONO Selected as Highest Rating A-List Company by CDP in Two Categories of “Climate Change” and “Water Security” in CDP 2023
-
- Feb.01.2024 Management / Finance
- Ono Announces Status of Acquisition of Own Shares
-
- Jan.31.2024 Management / Finance
- Announcement on Financial Results for FY2023 3Q
-
- Jan.29.2024 R & D
- Subcutaneous Nivolumab (nivolumab and hyaluronidase) Shows Noninferiority Compared to Intravenous Opdivo (nivolumab) in Advanced or Metastatic Clear Cell Renal Cell Carcinoma in CheckMate -67T Trial
-
- Jan.23.2024 R & D
- Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Demonstrates Long-Term Survival Benefits After Four Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell Carcinoma
-
- Jan.23.2024 R & D
- Eight-Year Data for Opdivo (nivolumab) Plus Yervoy (ipilimumab) Continue to Demonstrate Longest Survival Benefit vs. Sunitinib Reported in Patients with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma
-
- Jan.22.2024 R & D
- Opdivo (nivolumab) Plus Yervoy (ipilimumab) Reduced the Risk of Disease Progression or Death by 79% Versus Chemotherapy in Patients with Microsatellite Instability–High or Mismatch Repair Deficient Metastatic Colorectal Cancer in CheckMate -8HW Trial
-
- Jan.11.2024 Corporate
- Notice of Changes in Representative Directors
-
- Jan.09.2024 Corporate
- Support for Disasters Caused by the 2024 Noto Peninsula Earthquake
-
- Jan.09.2024 R & D
- Fate Therapeutics Announces Initiation of Phase 1 Clinical Trial for FT825 / ONO-8250 in Patients with HER2-expressing Advanced Solid Tumors
-
- Jan.05.2024 Management / Finance
- Ono Announces Status of Acquisition of Own Shares